Dr. Cohen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3855 Health Sciences Dr.
San Diego, CA 92093Phone+1 858-534-6161- Is this information wrong?
Summary
- I am a board-certified oncologist and cancer researcher. I care for patients with all types of head and neck cancers, including esophageal, thyroid and salivary gland cancers.
Much of my work has focused on squamous cell carcinomas and cancers of the thyroid, salivary gland, and HPV-related oropharyngeal cancers. As a physician-scientist, he is especially interested in developing novel therapies and understanding mechanisms of sensitivity or resistance; cancer screening; and using medication and other agents to delay or prevent cancer (chemoprevention). Additionally, I was recently appointed chair of the National Cancer Institute Head and Neck Cancer Steering Committee, which oversees NCI-funded clinical research in this disease.
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 1999 - 2002
- Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1996 - 1999
- University of Toronto Faculty of MedicineClass of 1990
Certifications & Licensure
- IL State Medical License 1999 - 2026
- CA State Medical License 2014 - 2024
- MA State Medical License 2011 - 2017
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Start of enrollment: 2004 Nov 01
- Rapamycin With Grapefruit Juice for Advanced Malignancies Start of enrollment: 2006 Sep 01
- Erlotinib Prevention of Oral Cancer (EPOC) Start of enrollment: 2006 Nov 03
- Join now to see all
Publications & Presentations
PubMed
- Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence.Poorva Vaidya, Ezra E W Cohen> ;Clinical Cancer Research. 2024 Apr 1
- An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer.Karen M Yun, Ezra E W Cohen> ;JCO Oncology Practice. 2024 Mar 7
- A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer.Aaron M Miller, Zeynep Koşaloğlu-Yalçın, Luise Westernberg, Leslie Montero, Milad Bahmanof, Angela Frentzen, Manasa Lanka, Ashmitaa Logandha Ramamoorthy Premlal, Grego...> ;Science Translational Medicine. 2024 Feb 28
- Join now to see all
Lectures
- Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic ...2019 ASCO Annual Meeting - 6/1/2019
- Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) i...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- ECHO-310: A phase 3, randomized trial of epacadostat + nivolumab + chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Join now to see all
Press Mentions
- Testing COVID Vaccine? Fighting Cancer? Carlsbad 6-Year-Old Does BothOctober 9th, 2021
- Another FGFR Inhibitor Active in Bile Duct CancersApril 13th, 2021
- Infinity Pharmaceuticals Presents New MARIO-1 Phase 1/1b Clinical Data at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual MeetingNovember 9th, 2020
- Join now to see all
Hospital Affiliations
- UC San Diego Medical Center - HillcrestSan Diego, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: